Pharmacia Aktiebolag

Kabi Pharmacia Ab

Pharmacia & Upjohn Aktiebolag

Synphora Ab

Pharmacia Ab

Pharmacia & Upjohn Ab

Columbia University

Kabi Pharmacia

Synphra Ab

Pfizer Health Ab

Johan W Stjernschantz

Bahram Resul

Laszlo Z Bito

Staffan Lake

Philip Hoyng

Helge Rask-Andersen

Goran Selen

A novel method and compositions for the local treatment of Meniere's disease, tinnitus and hearing loss are described. The treatment is based on the administration of a therapeutically effective amount of a prostaglandin of the F-type to the inner ear. The treatment can be either continuous or intermittent and may involve the use of pumps, gels, or slow release drug inserts.

Method and compositions for local treatment of Meniere's disease, tinnitus and/or hearing loss

The invention relates to ophthalmological compositions for topical treatment of glaucoma or ocular hypertension comprising an effective intraocular pressure reducing amount of a prostaglandin derivative of PGA, PGB, PGD, PGE or PGF, in which the omega chain contains a ring structure, in an ophthalmologically compatible carrier. The invention further relates to the preparation of said compositions and their use for treatment of glaucoma or ocular hypertension.

Prostagladin derivatives for the treatment of glaucoma or ocular hypertension

A selective EP or EP prostanoid receptor agonist can be used to treat female sexual dysfunction. Salts and esters of the agonists can also be used. Formulations comprising such agonists, salts, or esters can be in the form of a cream, gel, ointment, or solid, useful for topical administration.

Method for treatment of female sexual dysfunction

This invention is related to a method whereby scar formation in the drainage fistula and subconjunctival bleb created during and after glaucoma surgery using a prostaglandin subtype A or J.

Method and composition for prevention of scar formation in glaucoma filtration bleb and drainage fistula

Compositions and methods for treatment of impotence or erectile dysfunction employ prostaglandins that are selective EP or EP prostanoid receptor agonists. The compositions can be formulated for intracavernous injection, or for transurethral or transdermal application.

Method and composition for treatment of erectile dysfunction

Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension

Molecular cloning and expression of a prostaglandin F2&agr; receptor which is linked to the signal transduction pathways via guanine nucleotide binding regulatory (G) proteins and measured by, for example, cAMP, IP or intracellular calcium. By constructing cell lines that express a prostaglandin F2&agr; receptor, the affinities and efficacies of agonist and antagonist drugs with the receptor can be assessed. A recombinant DNA construct includes a vector and a DNA fragment encoding a prostaglandin F2&agr; receptor. A host cell is transformed with a recombinant DNA construct, so that the DNA fragment is expressed and a prostaglandin F2&agr; receptor is produced. Suitable host systems include eukaryotic and prokaryotic cells, especially mamalian cells such as rat or human. Additionally, for diagnostic purposes, antibodies to a prostaglandin F2&agr; receptor can be prepared by producing all or a portion of the receptor protein and injecting these into various types of mammals. Using the resulting antibodies, expression of an F2&agr; receptor cDNA, i.e. receptor protein in tissue and cells can be measured.

DNA encoding a prostaglandin F2&agr; receptor, a host cell transformed therewith and an expression product thereof

Growing community of inventors

Uppsala, Sweden

Johan W Stjernschantz